FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 319:257-262 August 4, 1988 Number 5 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We retrospectively studied 28 patients with 38 episodes of newly occurring ventricular fibrillation during antiarrhythmic drug therapy. Twenty-six of these patients, who had ventricular fibrillation during single-drug therapy with quinidine, procainamide, or disopyramide, were compared with a control group of 62 patients who had been treated similarly for ventricular arrhythmias but did not have ventricular fibrillation during treatment. The median duration of therapy before ventricular fibrillation was three days. The left ventricular ejection fraction of the study group was lower than that of the control group (0.29 vs. 0.43; P less than 0.0001), and concomitant treatment with digitalis and diuretic agents was more common in the study group. The base-line QT interval (corrected for heart rate) was slightly longer in the study group than in the controls (0.47 vs. 0.44; P less than 0.005), although both groups had similar degrees of QT prolongation during drug therapy. Four of 13 patients (31 percent) who underwent multiple trials of antiarrhythmic drugs had recurrent episodes of ventricular fibrillation. Six patients died suddenly after a mean follow-up of 18 months--four who were receiving antiarrhythmic therapy and two who were not. We conclude that drug-associated ventricular fibrillation is an early event, that there may be an increased risk of its recurrence with subsequent trials of antiarrhythmic drugs, and that left ventricular dysfunction and concomitant therapy with digitalis and diuretic agents may predispose patients to this complication.

Source Information

Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis.

This article has been cited by other articles:

• Pratt, C. M., Al-Khalidi, H. R., Brum, J. M., Holroyde, M. J., Schwartz, P. J., Marcello, S. R., Borggrefe, M., Dorian, P., Camm, A. J., on behalf of the Azimilide Trials Investigators, (2006). Cumulative Experience of Azimilide-Associated Torsades de Pointes Ventricular Tachycardia in the 19 Clinical Studies Comprising the Azimilide Database. J Am Coll Cardiol 48: 471-477 [Abstract] [Full Text]  
• lost, N., Virag, L., Varro, A., Papp, J. Gy. (2003). Comparison of the Effect of Class IA Antiarrhythmic Drugs on Transmembrane Potassium Currents in Rabbit Ventricular Myocytes. J CARDIOVASC PHARMACOL THER 8: 31-41 [Abstract]  
• Firouzi, M., Groenewegen, W. A. (2003). Gene polymorphisms and cardiac arrhythmias. Europace 5: 235-242 [Full Text]  
• Abbott, G. W., Goldstein, S. A. N. (2001). Potassium Channel Subunits: The MiRP Family. Mol. Interv. 1: 95-107 [Abstract] [Full Text]  
• APPLEBY, L., SHAW, J., AMOS, T., THOMAS, S., FERRIER, N., LEWIS, G. (2000). Sudden unexplained death in psychiatric in-patients. Br. J. Psychiatry 176: 405-406 [Full Text]  
• Cannom, D. S., Prystowsky, E. N. (1999). Management of Ventricular Arrhythmias: Detection, Drugs, and Devices. JAMA 281: 172-179 [Abstract] [Full Text]  
• Grace, A. A., Camm, A. J. (1998). Quinidine. NEJM 338: 35-45 [Full Text]  
• Sharma, P. P., Ott, P., Hartz, V., Mason, J. W., Marcus, F. I. (1998). Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial. J CARDIOVASC PHARMACOL THER 3: 269-274 [Abstract]  
• (1988). WHEN ARE ANTI-ARRHYTHMIC DRUGS PRO-ARRHYTHMIC?. JWatch General 1988: 8-8 [Full Text]  
• Sesti, F., Abbott, G. W., Wei, J., Murray, K. T., Saksena, S., Schwartz, P. J., Priori, S. G., Roden, D. M., George, A. L. Jr., Goldstein, S. A. N. (2000). A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA 97: 10613-10618 [Abstract] [Full Text]